Mersana Therapeutics, Inc. announced a 1-for-25 reverse stock split of its common stock, effective July 25, 2025, to increase market price and comply with Nasdaq listing requirements. The split will reduce outstanding shares from 124.8M to 5.0M, with adjustments to equity incentive plans. No fractional shares will be issued. Shareholders need not take action for post-split shares. Additional information is available in the Proxy Statement. Mersana focuses on developing ADCs for cancer treatment, with products like Emi-Le and XMT-2056 in its pipeline. Forward-looking statements caution that actual results may differ from expectations. Contact Jason Fredette for more information.

Read more at GlobeNewswire: Mersana Therapeutics Announces 1-for-25 Reverse Stock